New pill aims to tackle Huntington's at its source
Disease control
Recruiting now
This clinical trial tests an oral drug called SKY-0515 in 400 adults with Huntington's disease. The goal is to see if it can lower harmful proteins linked to the disease and improve symptoms like movement and thinking. Participants take the drug or a placebo daily for 18 months.
Phase: PHASE2, PHASE3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 07:00 UTC